Literature DB >> 20389157

Use of Memokath 051 metallic stent in the management of ureteral strictures: a single-center experience.

Georgios I Papadopoulos1, Seshikanth Middela, Shalom J Srirangam, Cezary A Szczesniak, Poduri N Rao.   

Abstract

INTRODUCTION: Memokath 051 represents a nickel-titanium stent that has been used to treat patients with incurable ureteral strictures. In the current study we present our experience in using this technique.
MATERIALS AND METHODS: Between 2003 and 2008, 19 metallic stents were placed in 13 patients. All of them had been previously treated by using JJ stents or dilatation. The etiology was benign in 10, while in 3 patients malignancy was involved. The mean age was 60.7 years. Mean stricture length was 3.2 cm while the median stent length was 6 cm. No severe complications were noticed postoperatively. Mean follow-up was 14.3 months.
RESULTS: Six patients (46%) experienced a satisfactory result after first insertion. Stent migration was observed in 6 patients and in 3 it was replaced successfully. One patient was offered a simple nephrectomy due to a poorly functioning kidney. Eventually, 10 of 13 patients (77%) had a successful outcome after the final stent insertion.
CONCLUSION: Memokath stents suggest a possible alternative in treating chronic/recurrent ureteral strictures. Their most important disadvantage seems to be migration. Their role in endourological practice remains to be validated. Copyright 2010 S. Karger AG, Basel.

Entities:  

Mesh:

Year:  2010        PMID: 20389157     DOI: 10.1159/000288230

Source DB:  PubMed          Journal:  Urol Int        ISSN: 0042-1138            Impact factor:   2.089


  2 in total

1.  A novel approach for removing an intra-renal migrated Memokath™ stent.

Authors:  Naveen Kachroo; Andrew D Simpson
Journal:  Int J Surg Case Rep       Date:  2013-08-03

Review 2.  The Memokath-051 Stent for the Treatment of Ureteric Obstruction: A NICE Medical Technology Guidance.

Authors:  Emily Eaton Turner; Michelle Jenks; Rachael McCool; Chris Marshall; Liesl Millar; Hannah Wood; Alison Peel; Joyce Craig; Andrew J Sims
Journal:  Appl Health Econ Health Policy       Date:  2018-08       Impact factor: 2.561

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.